Examination of the relationship of image on the morphological changes and prognosis by XELOX + bevacizumab therapy in the healing unresectable advanced or recurrent colorectal cancer with liver metastasis
- Conditions
- colon cancer
- Registration Number
- JPRN-UMIN000015035
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1) On the image, brain metastases are found, or from clinical symptoms, brain metastasis is suspected. (2) Cerebrovascular neuropathy, or with a history within one year prior to enrollment. It has been conducted surgery within 4 weeks. (3)Prior to enrollment, biopsy with incision, the suture treatment for trauma, or have implemented fine-needle aspiration cytology within 1 week. (4) Traumatic fracture not healing (5) Bleeding tendency, or to have a coagulopathy. (6)The administration of an anti-thrombotic agent for thrombosis within 10 days before registration (7) Require the administration of aspirin formulation of 325 mg or more. (8) It has with symptoms at the time of registration and the (corresponding to grade 2 or more in Ver.3.0 Japanese translation JCOG / JSCO version NCI-CTCAE) heart disease or are doing some kind of treatment. Alternatively, there is a history of myocardial infarction within one year prior to enrollment. (9) on the image, a body cavity fluid requiring treatment. (10)Digestive cancer carcinoma in situ of the cervix and skin basal cell carcinoma, or by endoscopic mucosal resection endoscopic, healing has been confirmed, transition is not observed overlap cancer of less than five years was (healing disease-free interval it has to a) except for the prostate cancer (11) And has a neuropathy of grade 1 or more Ver.3.0 Japanese translation JCOG / JSCO version NCI-CTCAE (12)Pregnant women, lactating women, pregnancy test positive. Or, patients with no intention to contraception. (13) Oxaliplatin, or with a history of hypersensitivity to severe capecitabine (14) Suspected (DPD) deficiency dihydropyrimidine dehydrogenase, adverse reactions to fluoropyrimidine drugs was expressed. (15)Investigator deems inappropriate to participate in the test (16)The cases with serious complications (uncontrolled digestive ulcer, hypertension, diarrhea, infections, gastrointestinal perforation, such as interstitial pneumonia or pulmonary fibrosis)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OS
- Secondary Outcome Measures
Name Time Method PFS,ORR,Safety